Molnupiravir: A New Hope For Prevention And Treatment Of Covid-19 And Other Dangerous Viruses A new Covid-19 therapy has completed its phase two human trial and the results are promising. Molnupiravir, developed by Ridgeback Biotherapeutics LP and Merck & Co., reached its endpoint objective of reducing the length of Covid-19 infections, according to a Merck press release.